Home Vision Products Your Business Partner Visionary Knowledge About Us Find optician Contact us Country An estimated 5 billion people, or half the global population, could be affected by myopia by 2050. Myopia is a global concern. Annual myopia progression rate is most rapid under 10 years of age. Significantly greater rates of progression can be seen especially in children with high myopia. If left untreated, myopia can lead to lasting vision problems. But together we can tackle myopia in children. An innovative spectacle lens. This spectacle lens based on revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) Technology was developed in cooperation with The Hong Kong Polytechnic University in 2014. MiYOSMART is easy to fit, just like regular single vision lens. There are no limitations for the frame choice. In 2018, the MiYOSMART lens won the Gold Prize, Grand Award & Special Gold Award International Exhibition of Inventions of Geneva, Switzerland. In 2020, it won the Silmo d’Or Award in the Vision category at the Silmo Paris Optical Fair. A revolutionary technology. With the exclusive non-invasive D.I.M.S. Technology, the lens corrects the visual defect on its entire surface and has a ring shaped treatment area to slow down myopia progression. The alternation of the focus area and defocus area provides clear vision and manages myopia simultaneously. Published scientific studies in the British Journal of Ophthalmology: Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. (Published 11 Dec. 2019) read article Myopia control effect of Defocus Incorporated Multiple Segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. (Published Online First: 17 March 2021) read article Designed to fit a child’s active life. MiYOSMART comes with an easy-to-wipe special anti-reflective, durable coating. With its Eye Shield, young patients get the added assurance of an impact resistant material and UV protection. *PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S. 1 Brien Holden Vision Institute; 2 Shanghai Eye Disease Prevention and Treatment Center https://guidelines.brienholdenvision.org, accessed 16.08.1018. 2 Lam CSY, Tang WC, Lee RPK, Chun RKM, To CH. A randomized clinical trial for myopia control – use of myopic defocus spectacle lens. 8th International Congress of Behavioral Optometry (ICBO), 26- 29 of April 2018. Sydney, Australia. 8Sankaridurg P1, Tilia D1, Morton M1, Weng R1, Jong M1, Zhu F2. Guidelines for Myopia Management. Our Solutions Progressive lenses Single Vision Occupational lenses Photochromic Lenses Sun Solutions Special Lenses Lens Materials Coatings Your Business Partner Run an outstanding practise Deliver the best patient care Grow your knowledge Visionary Knowledge Visionary Knowledge About Hoya About Us Contact Us HOYA Vision Care News Careers Careers Country © 2021 HOYA - All rights reserved Privacy Policy Terms of use